RIPK3 and diabetic kidney disease: These results shed new light on the underlying pathogenic mechanisms of podocyte injury in DKD and highlight the therapeutic potential of mitigating podocyte injury through inhibition of the RIPK3/NF‐κB p65‐mediated inflammatory response as a viable treatment option for DKD (Figure 8).